NO914482L - Fremgangsmaate for behandling av kardial samt vaskulaer hypertrofi og hyperplasi - Google Patents

Fremgangsmaate for behandling av kardial samt vaskulaer hypertrofi og hyperplasi

Info

Publication number
NO914482L
NO914482L NO91914482A NO914482A NO914482L NO 914482 L NO914482 L NO 914482L NO 91914482 A NO91914482 A NO 91914482A NO 914482 A NO914482 A NO 914482A NO 914482 L NO914482 L NO 914482L
Authority
NO
Norway
Prior art keywords
hyperplasia
treatment
cardial
procedure
vascular hypertrophy
Prior art date
Application number
NO91914482A
Other languages
English (en)
Norwegian (no)
Other versions
NO914482D0 (no
Inventor
Holger Heitsch
Rainer Henning
Wolfgang Linz
Bernward Schoelkens
Hansjoerg Urbach
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO914482D0 publication Critical patent/NO914482D0/no
Publication of NO914482L publication Critical patent/NO914482L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Peptides Or Proteins (AREA)
  • Recrystallisation Techniques (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO91914482A 1990-11-17 1991-11-15 Fremgangsmaate for behandling av kardial samt vaskulaer hypertrofi og hyperplasi NO914482L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4036706A DE4036706A1 (de) 1990-11-17 1990-11-17 Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie

Publications (2)

Publication Number Publication Date
NO914482D0 NO914482D0 (no) 1991-11-15
NO914482L true NO914482L (no) 1992-05-18

Family

ID=6418475

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914482A NO914482L (no) 1990-11-17 1991-11-15 Fremgangsmaate for behandling av kardial samt vaskulaer hypertrofi og hyperplasi

Country Status (20)

Country Link
US (1) US5236943A (zh)
EP (1) EP0492105B1 (zh)
JP (1) JP3370347B2 (zh)
KR (1) KR100221686B1 (zh)
CN (1) CN1049116C (zh)
AT (1) ATE108656T1 (zh)
AU (1) AU652590B2 (zh)
BR (1) BR9104918A (zh)
CA (1) CA2055637C (zh)
CZ (1) CZ283236B6 (zh)
DE (2) DE4036706A1 (zh)
DK (1) DK0492105T3 (zh)
ES (1) ES2060274T3 (zh)
HR (1) HRP940765B1 (zh)
HU (1) HU219404B (zh)
IE (1) IE66461B1 (zh)
MX (1) MX9102100A (zh)
NO (1) NO914482L (zh)
SK (1) SK280304B6 (zh)
ZA (1) ZA919056B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
CZ283315B6 (cs) * 1992-12-17 1998-02-18 Sankyo Company Limited Bifenylové deriváty, způsob výroby a farmaceutické prostředky k léčení hypertense a srdečních onemocnění, které tyto deriváty obsahují
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
DE69725171T2 (de) * 1996-12-10 2004-07-15 G.D. Searle & Co., Chicago Substituierte pyrrolylverbindungen zur behandlung von entzündungen
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
ES2154191B1 (es) * 1998-11-24 2001-10-16 Ferrer Int Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
US6740649B2 (en) 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
ITTO20040264A1 (it) * 2004-04-28 2004-07-28 Rotta Res Lab Spa Nuovi derivati pirrolici ad attivita' angiotensina-ii antagonista
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
JP4511550B2 (ja) * 2004-09-02 2010-07-28 テバ ファーマシューティカル インダストリーズ リミティド オルメサルタンメドキソミルの調製法
EP1784398A1 (en) * 2004-09-02 2007-05-16 Teva Pharmaceutical Industries Ltd Purification of olmesartan medoxomil
US20060258727A1 (en) * 2005-01-03 2006-11-16 Lilach Hedvati Olmesartan medoxomil with reduced levels of impurities
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
DK2315591T3 (en) 2008-08-15 2016-06-06 Nivalis Therapeutics Inc NOVEL PYRROLE INHIBITORS OF S-nitrosoglutathione-reductase as therapeutic agents
EP2318007B1 (en) 2008-08-15 2013-01-23 N30 Pharmaceuticals, Inc. Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
US8642628B2 (en) * 2008-08-15 2014-02-04 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase
CN102816126A (zh) * 2011-06-07 2012-12-12 中国药科大学 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488084A (en) * 1892-12-13 Blank-feeding device
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
DE4036645A1 (de) * 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung

Also Published As

Publication number Publication date
CS347191A3 (en) 1992-06-17
HRP940765B1 (en) 2000-08-31
CN1062289A (zh) 1992-07-01
DE59102259D1 (de) 1994-08-25
ATE108656T1 (de) 1994-08-15
AU8785891A (en) 1992-05-21
US5236943A (en) 1993-08-17
ES2060274T3 (es) 1994-11-16
ZA919056B (en) 1992-07-29
IE66461B1 (en) 1995-12-27
JP3370347B2 (ja) 2003-01-27
HRP940765A2 (en) 1997-08-31
HUT59599A (en) 1992-06-29
JPH04290823A (ja) 1992-10-15
EP0492105A2 (de) 1992-07-01
DE4036706A1 (de) 1992-05-21
CZ283236B6 (cs) 1998-02-18
BR9104918A (pt) 1992-06-23
SK280304B6 (sk) 1999-11-08
KR100221686B1 (ko) 1999-09-15
IE913992A1 (en) 1992-05-20
EP0492105A3 (en) 1992-07-29
HU219404B (hu) 2001-04-28
EP0492105B1 (de) 1994-07-20
AU652590B2 (en) 1994-09-01
MX9102100A (es) 1992-07-08
CN1049116C (zh) 2000-02-09
DK0492105T3 (da) 1994-11-07
NO914482D0 (no) 1991-11-15
HU913581D0 (en) 1992-01-28
CA2055637C (en) 2003-11-11
KR920009393A (ko) 1992-06-25
CA2055637A1 (en) 1992-05-18

Similar Documents

Publication Publication Date Title
NO914482D0 (no) Fremgangsmaate for behandling av kardial samt vaskulaer hypertrofi og hyperplasi
MY104140A (en) Substituted pyrrole, pyrazole and triazole angiotensin ii antagonists
DE69816109D1 (de) Substituierte imidazole zur behandlung von entzündlichen krankheiten
NO176049C (no) Analogifremgangsmåte for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-II-reseptorer
DE69322254T2 (de) Pyridyl-substituierte imidazole
HUT62575A (en) Process for producing substituted imidazole derivatives and pharmaceutical compositions comprising same
DE3874073T2 (de) Aromatasehemmende 4(5)-imidazole.
NO914263D0 (no) Indol- og benzimidazolsubstituerte imidazol- og benzimidazol-derivater
TR199501561A2 (tr) Imidazol türevleri.
MA22869A1 (fr) Nouveaux derives triazole et imidazole fongicides .
DK600788D0 (da) Triazol- eller imidazolforbindelser, fremgangsmaade til fremstilling deraf og anvendelse af saadanne forbindelser som fungicider
IS3985A (is) Aðferð við framleiðslu á 1,2,3,9-tetrahýdró-9-metýl-3-[(2-metýl-1H-imídazól-1-ýl)metýl]-4H-karbasól-4-ón
FI973845A0 (fi) Imidatsoli-, triatsoli- ja tetratsolijohdannaisia